Annals of Laboratory Medicine

  • 제35권2호
  • /
  • Pages.226-232
  • /
  • 2015
  • /
  • 2234-3806(pISSN)
  • /
  • 2234-3814(eISSN)
대한진단검사의학회 (Korean Society for Laboratory Medicine)
권호 표지
DOI QR코드

DOI QR Code

Quantitative Measurement of Serum MicroRNA-21 Expression in Relation to Breast Cancer Metastasis in Chinese Females

  • Wang, Guinian (Department of Laboratory Medicine, The First Hospital of Zibo City) ;
  • Wang, Longzi (Department of Pharmacy, Zibo Vocational Institute) ;
  • Sun, Sijing (Department of Surgical Medicine, The First Hospital of Zibo City) ;
  • Wu, Juan (Department of Laboratory Medicine, The First Hospital of Zibo City) ;
  • Wang, Qinglu (Key Laboratory of Biomedical Engineering, Shandong Wanjie Medical College)
  • 투고 : 2014.08.04
  • 심사 : 2014.12.29
  • 발행 : 2015.03.02
⟨ 이전 논문 다음 논문 ⟩

초록

Background: Breast cancer is the most common type of cancer in females. Aberrant expression of microRNA-21 (miR-21) has previously been reported in breast cancer tissue. The aim of this study was to investigate expression levels of serum miR-21 in breast cancer patients and evaluate its prognostic value in Chinese females. Methods: Real-time quantitative (RQ)-PCR was used to analyze miR-21 expression in archived serum, tumor tissue, and adjacent normal tissue from 549 participants (326 with breast cancer, 223 without breast cancer). We also analyzed associations between serum miR-21 expression and breast cancer subtypes and patient prognosis. Recurrence and survival were analyzed by using the multivariate Cox proportional hazards model. Results: Expression of miR-21 was significantly higher in breast cancer tissues compared with normal adjacent breast tissues (P<0.001). The $2^{-{\Delta}{\Delta}Ct}$ values for serum miR-21 in breast cancer patients versus healthy controls were $9.12{\pm}3.43$ and $2.96{\pm}0.73$, respectively. Multivariate Cox proportional hazards model suggested that serum miR-21 expression was an independent poor prognostic factor for both recurrence (hazard ratio [HR]=2.942; 95% confidence interval [CI]=1.420-8.325; P=0.008) and disease-free survival (HR=2.732; 95% CI=1.038-7.273, P=0.003) in breast cancer. Conclusions: Increased serum miR-21 expression level was correlated with poor prognosis of breast cancer patients, indicating that serum miR-21 may be a novel prognostic marker for recurrence and survival of breast cancer patients before resection.

키워드

과제정보

연구 과제 주관 기관 : First Hospital of Zibo City, Natural Scientific Foundation of Shandong Province

참고문헌

  1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin 2011;61:69-90. https://doi.org/10.3322/caac.20107
  2. Wightman B, Ha I, Ruvkun G. Posttranscriptional regulation of the heterochronic gene lin-14 by lin-4 mediates temporal pattern formation in C. elegans. Cell 1993;75:855-62. https://doi.org/10.1016/0092-8674(93)90530-4
  3. Michael MZ, O'Connor SM, van Holst Pellekaan NG, Young GP, James RJ. Reduced accumulation of specific microRNAs in colorectal neoplasia. Mol Cancer Res 2003;1:882-91.
  4. Calin GA, Sevignani C, Dumitru CD, Hyslop T, Noch E, yendamuri S, et al. Human microRNA genes are frequently located at fragile sites and genomic regions involved in cancers. Proc Natl Acad Sci USA 2004; 101:2999-3004. https://doi.org/10.1073/pnas.0307323101
  5. Wang F, Zheng ZG, Guo J, Ding X. Correlation and quantitation of microRNA aberrant expression in tissues and sera from patients with breast tumor. Gynecol Oncol 2010:119:586-93. https://doi.org/10.1016/j.ygyno.2010.07.021
  6. Cortez MA, Bueso-Ramos C, Ferdin J, Lopez-Berestein G, Sood AK, Calin GA. MicroRNAs in body fluids--the mix of hormones and biomarkers. Nat Rev Clin Oncol 2011;8:467-77. https://doi.org/10.1038/nrclinonc.2011.76
  7. Kishimoto T, Eguchi H, Nagano H, Kobayashi S, Akita H, Hama N, et al. Plasma miR-21 is a novel diagnostic biomarker for biliary tract cancer. Cancer Sci 2013;104:1626-31. https://doi.org/10.1111/cas.12300
  8. Zhao H, Shen J, Medico L, Wang D, Ambrosone CB, Liu S. A pilot study of circulating miRNAs as potential biomarkers of early stage breast cancer. PLos One 2010;5:e13735. https://doi.org/10.1371/journal.pone.0013735
  9. Edge SB, Byrd DR, Carducci M, Compton CC, Fritz AG, Greene FL, et al. eds. AJCC cancer staging manual. 7th ed. New York: Springer-Verlag, 2009.
  10. Asaga S, Kuo C, Nguyen T, Terpenning M, Giuliano AE, Hoon DS. Direct serum assay for microRNA-21 concentrations in early and advanced breast cancer. Clin Chem 2011;57:84-91. https://doi.org/10.1373/clinchem.2010.151845
  11. Mar-Aguilar F, Mendoza-Ramireza JA, Malagon-Santiago I, Espino-Silva PK, Santuario-Facio SK, Ruiz-Flores P, et al. Serum circulating microRNA profiling for identification of potential breast cancer biomarkers. Dis Markers 2013;34:163-9. https://doi.org/10.1155/2013/259454
  12. Chan M, Liaw CS, Ji SM, Tan HH, Wong CY, Thike AA, et al. Identification of circulating microRNA signatures for breast cancer detection. Clin Cancer Res 2013;19:4477-87. https://doi.org/10.1158/1078-0432.CCR-12-3401
  13. Iorio MV, Ferracin M, Liu CG, Veronesse A, Spizzo R, Sabbioni S, et al. MicroRNA gene expression deregulation in human breast cancer. Cancer Res 2005; 65:7065-70. https://doi.org/10.1158/0008-5472.CAN-05-1783
  14. Calin GA and Croce CM. Chromosomal rearrangements and microRNAs: a new cancer link with clinical implications. J Clin Invest 2007;117: 2059-66. https://doi.org/10.1172/JCI32577
  15. Qian B, Katsaros D, Lu L, Preti M, Durango A, Arisio R, et al. High miR-21 expression in breast cancer associated with poor disease-free survival in early stage disease and high TGF-${\beta}1$. Breast Cancer Res Treat 2009;117:131-40. https://doi.org/10.1007/s10549-008-0219-7
  16. Yan LX, Wu QN, Zhang Y, Li YY, Liao DZ, Hou JH, et al. Knockdown of miR-21 in human breast cancer cell lines inhibits proliferation, in vitro migration and in vivo tumor growth. Breast Cancer Res 2011;13:R2. https://doi.org/10.1186/bcr2803
  17. Kumar S, Keerthana R, Pazhanimuthu A, Perumal P. Overexpression of circulating miRNA-21 and miRNA-146a in plasma samples of breast cancer patients. Indian J Biochem Biophys 2013;50:210-4.
  18. Gao J, Zhang Q, Xu J, Guo L, Li X. Clinical significance of serum miR-21 in breast cancer compared with CA153 and CEA. Chin J Cancer Res 2013;25:743-8.
  19. Muller V, Gade S, Steinbach B, Loibl S, von Minckwitz G, Untch M, et al. Changes in serum levels of miR-21, miR-210, and miR-373 in HER2-positive breast cancer patients undergoing neoadjuvant therapy: a translational research project within the Geparquinto trial. Breast Cancer Res Treat 2014;147:61-8. https://doi.org/10.1007/s10549-014-3079-3
  20. Tamaki K, Ishida T, Tamaki N, Kamada Y, Uehara K, Miyashita M, et al. Analysis of clinically relevant values of Ki-67 labeling index in Japanese breast cancer patients. Breast Cancer 2014;21:325-33. https://doi.org/10.1007/s12282-012-0387-5
  21. Leivonen SK, Makela R, Ostling P, Kohonen P, Haapa-Paananen S, Kleivi K, et al. Protein lysate microarry analysis to identify microRNAs regulating estrogen receptor signaling in braest cancer cell lines. Oncogene 2009;28:3926-36. https://doi.org/10.1038/onc.2009.241
  22. Fackenthal JD and Olopade Ol. Breast cancer risk associated with BRCA1and BRCA2 in diverse populations. Nat Rev Cancer 2007;7:937-48. https://doi.org/10.1038/nrc2054
  23. Si ML, Zhu S, Wu H, Lu Z, Wu F, Mo YY. miR-21-mediated tumor growth. Oncogene 2007;26:2799-803. https://doi.org/10.1038/sj.onc.1210083
  24. Li J, Shen L, Xiao XG, Fang L. MicroRNAs in breast cancer and breast cancer stem cells and their potential for breast cancer therapy. Chin Med J 2013;126:2556-63.
  25. Tsujiura M, Ichikawa D, Komatsu S, Shiozaki A, Takeshita H, Kosuga T, et al. Circulating microRNAs in plasma of patients with gastric cancers. Br J Cancer 2010;102:1174-9. https://doi.org/10.1038/sj.bjc.6605608
  26. Wu Q, Wang C, Lu Z, Guo L, Ge Q. Analysis of serum genome-wide microRNAs for breast cancer detection. Clin Chim Acta 2012;413:1058-65. https://doi.org/10.1016/j.cca.2012.02.016
  27. Fu SW, Chen L, Man YG. miRNA biomarkers in breast cancer detection and management. J Cancer 2011;2:116-22. https://doi.org/10.7150/jca.2.116

피인용 문헌

  1. MiR-9 and miR-21 as prognostic biomarkers for recurrence in papillary thyroid cancer vol.32, pp.6, 2015, https://doi.org/10.1007/s10585-015-9724-3
  2. Activin A expression in esophageal carcinoma and its association with tumor aggressiveness and differentiation vol.10, pp.1, 2015, https://doi.org/10.3892/ol.2015.3248
  3. Milk—A Nutrient System of Mammalian Evolution Promoting mTORC1-Dependent Translation vol.16, pp.8, 2015, https://doi.org/10.3390/ijms160817048
  4. Folate status, folate-related genes and serum miR-21 expression: Implications for miR-21 as a biomarker vol.4, pp.None, 2015, https://doi.org/10.1016/j.bbacli.2015.06.006
  5. Identification of a circulating MicroRNA signature to distinguish recurrence in breast cancer patients vol.7, pp.34, 2016, https://doi.org/10.18632/oncotarget.10485
  6. MiR-328 May be Considered as an Oncogene in Human Invasive Breast Carcinoma vol.18, pp.11, 2016, https://doi.org/10.5812/ircmj.42360
  7. Tissue and Serum miRNA Profile in Locally Advanced Breast Cancer (LABC) in Response to Neo-Adjuvant Chemotherapy (NAC) Treatment vol.11, pp.4, 2015, https://doi.org/10.1371/journal.pone.0152032
  8. New Concepts in Cancer Biomarkers: Circulating miRNAs in Liquid Biopsies vol.17, pp.5, 2016, https://doi.org/10.3390/ijms17050627
  9. Downregulation of RUNX3 moderates the frequency of Th17 and Th22 cells in patients with psoriasis vol.13, pp.6, 2016, https://doi.org/10.3892/mmr.2016.5108
  10. Essential role of miRNAs in orchestrating the biology of the tumor microenvironment vol.15, pp.1, 2015, https://doi.org/10.1186/s12943-016-0525-3
  11. Prognostic value of circulating microRNA-21 for breast cancer: a systematic review and meta-analysis vol.45, pp.6, 2017, https://doi.org/10.1080/21691401.2016.1216856
  12. MicroRNA-205 promotes cell invasion by repressing TCF21 in human ovarian cancer vol.10, pp.None, 2015, https://doi.org/10.1186/s13048-017-0328-1
  13. Integrated Characterization of MicroRNA and mRNA Transcriptome in Papillary Thyroid Carcinoma vol.9, pp.None, 2015, https://doi.org/10.3389/fendo.2018.00158
  14. Tumor microenvironment and noncoding RNAs as co‐drivers of epithelial–mesenchymal transition and cancer metastasis vol.247, pp.3, 2018, https://doi.org/10.1002/dvdy.24548
  15. MicroRNA expression in pre-treatment plasma of patients with benign breast diseases and breast cancer vol.9, pp.36, 2015, https://doi.org/10.18632/oncotarget.25262
  16. Amperometric Biosensing of miRNA-21 in Serum and Cancer Cells at Nanostructured Platforms Using Anti-DNA-RNA Hybrid Antibodies vol.3, pp.8, 2018, https://doi.org/10.1021/acsomega.8b00986
  17. MicroRNA in diagnosis and therapy monitoring of early-stage triple-negative breast cancer vol.8, pp.None, 2018, https://doi.org/10.1038/s41598-018-29917-2
  18. Circulating microRNAs in the early prediction of disease recurrence in primary breast cancer vol.20, pp.None, 2015, https://doi.org/10.1186/s13058-018-1001-3
  19. Deregulated miRNAs in osteoporosis: effects in bone metastasis vol.76, pp.19, 2019, https://doi.org/10.1007/s00018-019-03162-w
  20. A new insight on serum microRNA expression as novel biomarkers in breast cancer patients vol.234, pp.11, 2015, https://doi.org/10.1002/jcp.28656
  21. Associations Between miRNAs and Two Different Cancers: Breast and Colon vol.12, pp.None, 2015, https://doi.org/10.2147/cmar.s227628
  22. Milk Exosomes: Perspective Agents for Anticancer Drug Delivery vol.21, pp.18, 2015, https://doi.org/10.3390/ijms21186646
  23. Prognostic Implications of microRNA-155, -133a, -21 and -205 in Breast Cancer Patients’ Plasma vol.10, pp.None, 2015, https://doi.org/10.2174/2211536610666210707114843